LV10185B - Anti-vomit and sedative preparation for prevention of seasickness - Google Patents

Anti-vomit and sedative preparation for prevention of seasickness Download PDF

Info

Publication number
LV10185B
LV10185B LVP-93-627A LV930627A LV10185B LV 10185 B LV10185 B LV 10185B LV 930627 A LV930627 A LV 930627A LV 10185 B LV10185 B LV 10185B
Authority
LV
Latvia
Prior art keywords
pct
methyl
prevention
seasickness
vomit
Prior art date
Application number
LVP-93-627A
Other languages
English (en)
Other versions
LV10185A (lv
Inventor
Gy Rgy Bodo
Jozsef Knoll
Eva Somfai
Sandor Virag
Ferenc Zak
Original Assignee
Chinoin Gyegyszer S Vegy Szeti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyegyszer S Vegy Szeti filed Critical Chinoin Gyegyszer S Vegy Szeti
Publication of LV10185A publication Critical patent/LV10185A/lv
Publication of LV10185B publication Critical patent/LV10185B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Description

LV 10185 IIpoTHBOpBOTHoe h ycnoKaHBaonee cpejucTBO Rja
ΠροφΟΒΚΤΗΚΗ MOpCKOŽ 60JI63HH
JfeoāpeTeHHe othochtch k očJiaeTH μθαμιιμηη m KacaeTCH MCn0JIB30BaHHS CpeflCTBa B Ka^eCTBe ΙφΟΤΗΒΟρΒΟΤΗΟΓΟ H ycnOKaHBa-iomero flJIH ΓφθφΗΛ?.ΚΤΗΚΗ MOpCKOH 6θΛΘ3ΗΜ.
UeJLbKJ Η3θδρ6Τ6ΗΜΗ HBJIH6TCH yCTpaH0HM6 ΠΟδΟΗΗΟΓΟ fleftCTBKH. HacTOHin,ee Η3οδρβτβΗΜθ KacaeTCH πρημοηθηηη rHapoxjiopMsa N-M6THJi-N-nponaprHJi-(2^HHJi-l-M6THJi)-3THJiaMHHa hjih N-Me- TMJi-N-nponaprHJi-C 2-( 4-φτορφ6Ηΐυι) -Ι-μθτμλ] -STunaMUHa b Ka^ecTBē npoTMEopBOTHoro h ycnoKaHBaioiii,6ro cpe^cTBa npn Μοροκοπ 6ojie3HH. IfeBecrao, hto ecjiH no^BapraTB HOJiOBena hjih hskotopbk mjic-κοπμτ&ιοιιιηχ ( t. e. κοιπθκ, coāaK) flJHiTejiBHOMy Harpy;K6HHio ehbihhhm Rmmumu hjih TpaHcnopTHpoBKe, cBH3aHKbiM c ηθοοηηηημη hjih cne- UJ/lcLJlbHkmi flBH^eHHHMH (T3KHMH, KaK Kanna, KOJI0OaT6JĪLHb!0 JļBiam-khh, KeoSbiHHbie aTmqc¢6ρ η βιθ· ycjioBHH, ooJiMioe ycKop6HH6, HepoB-hoctm floporn h TaK flaJiee), to noHBJUnoTCH xapaKTepHbie HejKejiaTejLbHbie h HeojiaronpHHTHbie φΜ3ΗοαιθΓΗηβοκΗ6 οημπτομβι. ynOMHHyTbie Bblllie ΟΗΜΠΤΟΜΗ OObiHHO Ha3bIBai0T "MOpCKOH δο-JiesHBio” (”hauxa maris") kmhotos, yKanHBaHHe b setomoomjib hjih b noesfle h TaK flajiee. Pa3yMeeTca, sto ne jieiiCTBHTSJiLKan ooJiesHh, Π 0 6 B -7IH ΏΙΙΙΗΧ C 6 y ,H6JIOB6Kci a KOMĪIJKKC φΗ3 HOJIO Γ HH6 C ΚΗΧ ΟΗΜΠΤΟΜΟΒ, B Ο Π p6 36 JI6 η Hb!X yCJIOBHnX.
ΠϋΗΒΛΘΗΗβ 3ΤΗΧ CHMTITOMOB 3aBHCHT OT HH3HBH30 Η 6Γ0 (.HJIH 66) npOApOMaJIL·HOΓΟ COCTOHHHH , TpēHHpOBah'KOCTH, ilpHBbiHcK H 0HO~
JlOnmeCKOro COCTOHHMH. ΠΟΗΒΛΘΗΗΘ 3ΤΗΧ ΟΜΜΠΤΟΜΟΒ MOJjST HafiJDO-saTbCH y Bcex naccajimpoE, nyTemeoTBy!oii!HX no B03ayxy mjim no mo- p!0, KO y H6K0T0pbiX JIKIļ OHM ΠΟΗΒΠΗίΟΤΟΗ T3K2C9 HpK Π063£Κβ K3 3.B T Ο Μ 3.ίΙΙΙΊ K 3.Χ, 3BT0(jyce, T pciMBclc, HJIM ΠΟΙΊ ΠΟβΐβΜΘ πα ΠΚφΤΘ, Ε3
Ka^ejiKK hjih KaHaTHoft flopore h tsk flajiee.
HeT Heo0xoflKMOCTH 00cyjĶiiaTb stk HēOJiaronpHHTHHe coctohhhh πολρο6ηο. JiMaa, noju>sysMimecH οοβρθμθκηημ TpancnopTOM, onenb
KeSjiaronpM- nacTo no^BepraiūTCH 3T0My coctoshhjo, κοτοροβ κρβκκ stho, ho h onacHo b cjiy*jaax, Kor^a nejioBe;-:y Ky:«HQ paooTaTb bo ΒρβΜΗ Π0β3ΑΚΜ KJT/I TpaHCnopTMpOBKM JUM BCKOpe nOCJie ΗΜΧ. TaKHM 0āpa30M, ΒΟΛΜΤβΛK 3BTOTpaHCΠΟρΤα, ΠΗϋυΤΗ CaM0JI8T03, KOCMOKSB-Tfcl, aCTpOHaBTbl, ΠΜΟΤΗ B0eHH0-B03flyiHHhfX CMJI HJDi ΟΠΟΟΤΟΜβΚΒΙ, KOMMepcaHTH, 6η3ηθομθηη m TaK RdJiee, kto EOjraBH nposBJKTB eh-coKyxi κ KOHiļeHTpHOOBciHH'fK) MHT0 JiektyajiBHyK3 Km $H3nqecKyio aK- THEHOCTb, οοτρο Hyj«HaX3TCH B ΠρθφΚΛ3ΚΤΜΚβ yiIOMHHyTOrO "ΚΗΚβΤΟ-sa". 3Ta ποτρβδκοοτΒ 20 Hacroaiuero ΒρβΜβκκ χευβκο ne ysoBJieTBopeHa. AHajioriraHO stom’/ κΜββτοπ ποτρβδκοοτΒ b προφΜΠδκτΗΚβ Hease-JiaTejibKbix ομμπτομοβ, ποηβληκμι^ιχοα npn πβρβΒ03Κβ MJieKonKramijra (T. e. ΓΜΓΚβΗΜ^βΟΚβΗ TpaHcnopTHpoBKa ΚΧΒΟΤΗΗΧ Η TaK flajiee, οοοτοηηηθ no oKOH^aHMH nepeB03KM κ T8K flajiae). ΚθΜΠ03ΗΙ#Μ, COflepMaipe ΟΚΟΠΟΛ&ΜΜΗ ( -5,7-3ΠΟΚΟΚΤρθΠΜΗΤ-ponaT), Stum nepBBMf npenapa?aMH, ηοπο.πβ>30Β3ηηβιμμ sjih προφη-JiaKTMKH MOpCKOii āOJie3KM.' OflHaKO 3T0T aJIKaJIGHfl HBJIH6TCH CHJIbHHM napacHMnaTOjaīKOM, κοτορΒίϋ BhisbiBaeT BHflKMbie pacTpožcTBa, noMpa-qeHne co3HaHwa, Mbime<iHyra cjiaāocTb, cyxocTb bo pTy κ nosTOMy ero HcnojibsoBaHHe He6e3onacHQ. B HacToamee ΒρβΜΗ npeflnpHKHMa- - 3 - LV 10185 ιστοί! noribiTKM ycTpa.HHTb ΗΘκοτορωβ ποδο^ΗΗΘ ηβλθημη, Bhi3UBaeMue cKonojiHMHHOM, nyT8M BBefleHMH ero ΒΗγτρίϊκοχΗο (Aviat, Space Enoiro. Med, 54(11), CTpaHMUH 934-1000).
Epyraa οοβριηο Hcnojib3yeMaa komīioshumk - £ μ μθ κ r nu ρ η h aT x -BKJIHj^aeT δ-ΧΛΟρΤΘΟφΗΛΗΗΟΒγυ COJIB N, N-flHMeTMJI-2-( ΑΜφβΗΜ5Μ&Τ0Κ-
P cmj STHJiaMMHa b KaqecTBe εκτηβηογο HHrpasHeHTa (aejnajiOH J. Din. Med. Assn. 160, CTpaHHUbi 755-760). KcnoJibsoBaHMe stom ķom-nosHUHM MeHee onacHo, ho ynoMHHyTasi komīigsbuhh προΗΒϋκβτ ohckb HeČJiaronpiiHTHoe οηοτβορηοθ ceflaTMsnoe aežcTBHe. flesajioH Henie-jiaTeJiLHHM oopasoM cKasbiBaeTCH Ha paSoTocnocoCHocTH m npoM3BO-flHTejn>HOCTM Tpy^a πρκ nepeMemeHHH κ nocjie sasepineHMH noēsti, B H6K0T0pbIX CJiyqaHX BOOOIHe MCKJIIOTaH ΒΟΗΚγΊΰ ΛΘΗΤβ,ΜΟΟΤΙ».
Hajiee ηββθοτηο, qxo khbhhtoh^ (coAepmntHH b KaqeeTse aft-τηβκογο HHrpaflueHTa BHHHOueTHHX) yMeHbinaeT ckūohhoctb raiKeT03y (Bodo, Hartmai Thorapia Hungarica, 27.2 (1979). HesocTaTKOM P
KaBHHTOHa HBJiHeTCH to, qīo ero ^eHCTBue προηβληθτοη tojibko qe-pe3 5-7 flHefi nocjie ββθαθηηη. OCHOBHbie fJčLKTOpbl Η6ΖρθφΗ3ΜΟΛΟΓίΙΗ KHHeT03a ΟϋβΑΤΗΜφίβ: BecTHāyjiapHbiiī peiļeriTop, ceT^aTKa rjiasa κ ceMaToqyBCT3H-TeJibHbie peuenTopbi HeoSbTJHO pas^pajKafCTCH ηβικκβηηθμ η Heseco-MocTbio. Pa3JiiiqHHe CTpyKTypbi pearwpyio πβτολογμμθοκη Ka HeoobnHbie paaspa^iTejiM b ueHTpajībHOH ηθρβηομ οκοτθμθ. PearaineĀ KoptJ γολοβηογο M03ra HEJineTCH rojioBOKpy3BeKJfe, ToniHOTa, rojioBHas OOJIb H COHJIKBOCTb. PeaKIļHH JIHMāM^eCKOK CKCTeMbI npOHBJIHeTCS B flenpeccKM. rHnoTaJiaMyc qepe3 ΓκποφΜ3 Bbi3biBaeT ycnJieHHoe Bbifle-jieHKe BasnpeccHHa, βΛρβΗοκορτϋκοτροπΗΟΓο rapMOHa, rapMOHa poc- - 4 -
Ta m PPL
EecTHGyjiflpHbiM M03jneqoK Bbi3biBaeT yepe3 BereTaTHBHjno Heps-Hyio CHCTēMj χολοληηΛ ποτ, DJieflHOCTb, noHJKKeHHyio flBHraTejibKyio ,$yKKUHio mJiyj[Kdi, cep/isqHO- cocyflwcTbie n EbixaTejibHbie pacTpožc- TBa. EecTHoyjiHpHm M03*eqoK Bbi3biBaeT τεκμβ psoTy ECJiefiCTBHe 06-pa30BaHMH Parvicallularis Reticularis (Brain Res., 270, 154-18) (cm. cxeMy 1).
HeMssecTeH to^ho οοτβκτ aTSKH jiercapcTBa, fleMCTBjfomero npGTMB KHH9T03a. ΟφφθΚΤΜΒΗΒΙΜΙΊ CpSiCTBaMPT HBJIHfGTCH ΙζθΗΤρΕΠΒΗΟ aTaKyionmfi aHTMX0Āmeņrmecmvi xhoci0īh h aflpeHeprjraecKuft acpefl-PHH Μ δΜφθΤΘΜΜΗ. AkTHBHOCTJE» φθΗΟΤΜΘΒΡίΗΒ., 0JĪOKHpymi,erO ρβΙΙΘΠΤΟ-pbi sonaMMHa M b xeMopeueiiTopHož 3one B03Cya®eHHa 6ojh ο^θηβ CJiaOcfī. θφφβΚΤΜΒΗΗΜΗ ΠρΟφΗ^ΚΤΜ^βΟΚΜΜΡΙ CpeflCTBaMH HBJIHiGTCH flP7FHe aHTHrMCTaMMHH, TaKHe K3K ,ΖίΡΙΜΘΗΓΡΙ^ρΜΗΒΤ, PHKJIH3aH Η ΙίΗ-HapM3HH. Β Ka^ecTse πθρκφβρΜ^βοκΗ aežcTByjojnjix cpe^cTB mojkko ynOMHHyTb flOMnep/īflOH.
EblJIO ΗβΟΟΧΟΛΡΙΜΟ KclHTM CpeflCTBO flJĪH ΠρΟφΜΛΕΚΤΗΚΜ "MOpCKOĀ OOJieSKM”, KOTOpoe fleŪCTEOBaJĪO Obl OblCTpO, Κβ BblShIEaJIO KaKHX“JIH_ oo noooqHbix RemTBmi m oes yxyflmeHHH $H3imec?:oH βκτηβηοοτη.
HacT0Hni.ee ΗβοδρθτβΗΗβ KacaeTcn cpescTBa, npHroflKoro ajlh ΠροφίυΐΒΚΤΗΚΗ HeJKeJiaTeJIL·ΗΗΧ H ΗΘδΛΒΓΟΠρΗΗΤΗΗΧ φΜ3ΚθΛΟΓ5Ι^0ΟΚΚΧ CHMIĪTOMOB, KOTOpbie nOHBJIHIOTCH y 3Λ0Ρ0ΒΗΧ JUOflepI MJIH ΜΛΘΚ0ΠΜΤ3Κ>- ’ ιρριχ, noflBep»eHHtix Heo6bWHOMy BHeniHeMy λβηλβηηιο (t. e. TpaHcnop-TupoBKe). UCOOeHH'O npeflnO^THTeJIbHblM npMMepOM aKTMBHbK MHrpaflPieHTOB οδπι,βΗ $opMyjibi 1 ηβληθτοη οοβ^ΗΗβΗΡίβ $opMyjibi 1A (eejierHJiPr^M*): LV 10185
(ΙΑ) Ακτκβηηθ HHrpajtueHTH m cnocočH hx nojiyyeHiiH oroicaHbJ b na-TeHTax ΒβΗΓρκίί N151090, N 154 655 η N167755.
Hcnojit30BaHHe sthx coeflHHeHMĀ b KaqecTBe ncHxocTHMyjiHTO-poB, aHTHflenpeccaHTOB, KaTa5ojureecraix epejfCTB h cpeflCTB rjiz noTepu Beca (noxyseHMH) onncaHO b naTeHTe Βθκγρηη N151090. On-TM^ecKM aKTHBHbie aHTHnoflbi h kx HcnojiB30BaHHe b KaqecTBe μηγη-OMTopa MOHoaMMHOKCMflasH onHcaHO B naTeHTe BeHrpMM N154655. IIpeflno^TMTejibHaH sosa cpeflCTB corjiacno MsoSpeTeHHK) b Kam-flOM OTfieJIBHOM CJiyqae COCTaBJBīeT okojio 10-20 μγ οΧΤΜΒΗΟΓΟ HHrpaflHeHTa oāmefi φορ.^/ϋΗ 1. ΠρΜ ποημρηθκηη πρχ pasosoM fiose 10-20 mt Kaltie 24 nāca KaSjGOflajiocB ysoBJie?BopMTeJiBHGe ooīpee cocTOHHMe k panee ynoMHHa3msiecH οημπτομη, nojiBjiHKJismecs BCJienc- TBMe Heo6biqHbix yc.coEHž nepeflBMJKBHHfl (TpaHcnopTHpoBKH) Hcqe3aiOT πρκ £Ji&iTejiBHOM nyTeniecTBHH.
Cpe^CTBO COTJiaCHO Η3θδρβΤ6ΗΗϊΟ OCOāeHHO BhlTOflHO MGJK8T 6bITī> ηρΜΜΘΗΘΗΟ IiaCCaJKHpaMH M JieT^HKaMH caMOJieTOB H EOJUiTēJIHMH ,Zipy-ΓΗΧ annapaTOB ( aBTOMaiHMH, Kopaojieii, B03flyiDHax JiažHepoB h Towy πο,ςοδΗΒΐχ).
CorjiacHO M3o6peTeHHKD oqeHB npnroflHa ausi BBefleHMH αθτημ, nOflBepraMĢiMCH HēOOfcMHbIM yCJIOBMHM TpaHCIIOpTHpOBKH (B CaMOJieTe, na KopaāJie).
PasoEan aojih λθτημ οοοτοεληθτ 3-5 μγ b TeqeHne cyroK b 3aBWCMM0CTH GT 3ēCa TēJia.
Akthbhhh HHrpaflHeHT MomeT 6brn> MHKaneyjmpoBaH Heooasa-
TeJibKG c kskhm-khoYRh HocĶTejieM. JKēJiaeMoe KOJi/r-iecTBo βικτηβηογο HHrpaa^eKTa, saKJiioueηηογο b jKSjiaTHHOByio Kancyjiy, mombt δωτ& ποτρθδπβκο KenccpeflCTBeHHO. HacTOHni.ee MsočpeTeHne BKJno^aeT, pa3yMeeTCH, Bce nepopajihHbie fiOBHbie φορΜΗ, T. e. φορΜΗ, npMrOflHbie fiJIH ΒΒβΒΘΗΜΗ ^βρβ3 POT.
CorJiacHO npeHrmTHTeJiBHOM'/ BapnaHTy ocyiiļecTEJīeHHH H300pe-τβΚΜΗ aKTHBHbift HHrpajiHeHT npeflCTasjieH b φορΜθ flpaa© hjim TaS-jieTKH, noKpbiTOH caxapOM v.m moKOJia^oM. Ακτηβημ# MHrpaflHSHT BBefles b cepeflMHy. ΚΟΜΠΟΒΜΙΝίΗ COfJiaCKO ΜΒΟΟρβΤβΗΜ) flcUIēe MOJBST ČfcITb Η3Γ0Τ0Β-
Jiena B φορ.Μβ οΗβ^κηριχ npenapaTOB: TBepsux cjraflocTež (κοηΦθτ, JieaeHUOB, cJiasocTeii, nugates, MapusmaHOB, Heo6s3aTejn>Ho b ca-xape hjih noKpbiTbK moKOJiaflOM, cMeniaHHbie cjesocth, KapaMejm, flpaae c ποκρβιτηθμ μ b οοοοθηηοοτη rjssl seT e ž- »e bst ejilMan pe3H-Ha, cHpon h cyxož cnpon. /ļOOaBKM Onpe^eJIHiCTCH BHeniKeH ΗΟρΜΟίϊ Κ0ΜΠ03ΗΙΧΗΗ. TaKHM 00-pasoM MoryT οβιτβ HcnoJiBsoBaHU TpaflHiBfOHHue h ofitraHo πρημθηηθ-Mbie soūaBKM KOHflHTepcKoro nponsBOflCTBa (t. e. caxapo3a,
KpaXMajIBHblM paCTBOp). KoMIIOSHUMM COrJtaCHO 5ϊ3θ6ρβΤβΚΜίΟ ΓΟΤΟΒΗΤ HSBēCTHbIMM pOl' se MeTO^clMM KOHflvITepCKOM ΠρΟΜΗΙΜΟΗΗΟΟΤΗ.
Aktmbhhā HHrpaflHeHT oomen $opMynbi 1 oSbr-iHO jŅicnepnipoBaH B TenJIOH Κ0ΜΠ03Η!5ΗΗ. AKTHBHbie HHrpa^MeHTbi προφΗJiaKTmecκκχ komiiosmumž cornacHO m MSoGpeTeHHio MoryT Gbitb nojiy^eHbi MssecTHbiMH cnocoāaMH, onn-CaHHblMbl E ΠΕΤΘΗΤΒΧ ĒeHFpHH MM 151090, 154655, 187755 X B 3-3HB- - 7 - LV 10185
Ke Ha naTeHT BeHrpnM cep. HOMep 2124/84. IIojiyqeHHe οπτΗΗβοκΗΧ εκτηβηηχ cGenHHeHHft onjicaHO b naTeH-Tax BeHrpuM MN 154658,' 187755 m b sanBKe Ha naTeHT BeHrpM N 2142/84. M3o6peTeHHe MJuirocTpnpjeTCH cnenyioiiiHM npHMepoM. ΠρΗΜβρ.
PicnUTaHHH aKTHBHOCTH.
McrihiTaHHH Ha JIJOflHZ npOBO^HJIH Ha SnopOBbK MOJIOflbK MyaWMHaX b B03pacTe 18-23 jieT. ΦΗ3Η^βοκοβ οοοτοηημθ KaHnnnaTOB KOHTpojrapo-flo BBefleHHH: X = 8,58, nocjie BBeneHMS: X = 14,68 T = 2,568 J - 3,65 J = 6,97 3HanMTejLbHoe.
MoJfflo BHfleTB, ητο BpeMfl ρθβηοτθητηοοτμ yjiymuHJiocīi c 8,58 MMHyT (T = -2,568). 3to yjiynineHHe ηβχηθτοη SHanMTeiibHbiM. II. IDiaLieāo. no BBefleHHH: X = 3,87, nocjie B3eneHHH: X = 6,25 T = -1,64 J = 2,33 J = 4,18 BHanHTejiBKoe. B CJiynae c njiaueāo yBejmnMJiocb c 3,87 mhhtt no 6,25 mhhtt (T = 1,64) h 3to yjiyqffleHHe He3Ha^MTejibKoe). III. fleflajioH. no BBeneHHH: X = 4,4, nocne BBeneHHH: X = 11,53 T = 3,858 J = 2,34 J = 7,3 3Ha^HTejibHoe.
Pe3HCT6HTHoe BpeMH yBemmmcb c 4,4 MMHyTbi no 11,53 mh-Hyrbi (T » -3,058), t. e. HSMeHeHHe ηβληθτοη 3HanMTejibHbiM. 9T06bI OUeHHTb, HBJIHeTCH JIM pa3JIHHHe Me»ny aKTHBHOCTbK) ce-jierHjmyMa η nenanoHa 3HanHTejibHbiM, npoBejra cūenyioiiine pacneTbi: - 8 - X = 6,1 X = 7,13 J = 4,23409 J = 6,7743 Γ = 20 P(5%) - 2,886
TaKMM oopasoM, qTo KacaeTca βρθμθηη ρβ3ΗθτβΗτκοοτΗ, to 3HaqHTeJIbH0ii paSHMUU Me}K£y 3THMH flByMH Κ0ΜΠ03ΗΙ1ΜΗΜΗ H8T.
TecT Ha HcntiTaHHe bhmmcihmh noKaahiBaeT HesHaOTejiBHoe M3-MOHSHHe fiBJHviH Κ0ΜΠ03ΜΗΗΗΜΚ
CjoBeKTHBHbie HccjisjiOBaHMH očKapyaoiBaiQT, τβΜ He MeHee, CJieflyiomHe pe3yjii>TaThi: - njiaiļefio He BhisbmaJio Boodme ηηκβκμχ Μ3Μ6Η0ηημ; - nofl ne^cTBMēM flefiajioHa no^onbīTKbie jmiļa CTaaoBHJBicb coh-HbiMH, ycTajibiMM h sacbjnajm nocjie JicuuTaKKĀ; - nofl fležcTBHeM cejierejMHyMa ofiupe οοοτοηημθ CTaHOBHJiocb npiiHTHbiM (o'jKHBJieHHbiM) κ ποαοπητηηθ juma ne 3acanajDi. B HacToamee EpeMS HeB03M0«H0 fiaTL KeoflHosna^oe οοβηοηθ-ΗΜβ MexaHH3Ma flečīCTBHH Κ0ΜΠ03ΗΙϋΙΙ1 COrJiaCHO H30ČρβΤ6HHfO. KaK cjieflyeT H3 οό3οροΒ JiKTepaTyphi, iļepeopaoibHoe flonaMHHeprJuiecKoe CTHMyjmpoBaHHe, t. e. ocHOBaHHoe Ha ηββθοτηοη napajui3yioineft mo-HoaMMHOKCHJia3y aKTHBHOCTH cejierHJiHHyMa, He aefiCTByeT mjih Jimib cjiaoo aežcTByeT Ha γηηθτο3, to μη μο»θμ saTB 53a oCbHCHeHHH TOMy $aKTy, <JT0 ΚΗΗΘΤ03, Bbl3BaHHb!M CTMMyJIGM HOpHOJIHoa, 3HaUH-TejibHo cHHiKaeTCH riiflpoxjiopHflOM cejieriiJiHHyMa: 1) noBbuneHHe ypoBHH flonaMHHa, a πρκ ycTaKOBJieHHož HeflāBHo oāpa30BaHHM Parvicellularis Retcularis npHBOflirr κ ocjiaojieHHīo pBOTH. 3το 0y3eT nepBbiM JieKapcTBeHHbiM cpeacTBOM TaKoro copTa; 2) cejievmmvu rHflpoxjiopnfl He /ieMCTByeT nyTeM noBbnneHMH ypoBHH flonaMHHa, a fieteByeT KaKOH-το eme κθηββθοτηηη, otjuti-Hb$ ΟΤ 3Τ0Γ0 MexaHH3M.

Claims (1)

  1. LV 10185 IZGUDROJUMA FORMULA PRETVEMŠANAS UN NOMIERINOŠS LĪDZEKLIS JŪRAS SLIMĪBAS PROFILAKSEI. Metil-propargil-(2-fenil-1-metil)-etil-aminohidrohlorīda vai N-metil-N-propargil-[2-(4-fIuorfenīI)-l-metilj-etilamīna pielietošana kā pretvemšanas un nomierinošu līdzekli jūras slimības profilaksei. LV 10185 I ΠρΗΜΘΗΘΗΗθ rHJipOKJIOpHfla -M0THJI- - ΠρΟΠΕρΓΗΛ- /2-φβΗΚΛ-1 - Μθ" THJl/-3TIlJiaMMHa HJffl Ν-ΜβΤΜΛ-Ν-Πρ0Π3ρΓΗΛ-[2-(4-φΓ0ρφβΗΪ!Λ)-1-Μβ-tmjij -aTMJiaMMHa e KaqeeTBe npoTKBopBOTHoro m ycnoKawBaiomero cpeflCTBa npn Μοροκοίί 6ojie3HH.
LVP-93-627A 1986-12-19 1993-06-19 Anti-vomit and sedative preparation for prevention of seasickness LV10185B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU865338A HU197510B (en) 1986-12-19 1986-12-19 Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
PCT/HU1987/000058 WO1988004552A1 (en) 1986-12-19 1987-12-18 Composition to prevent seasickness

Publications (2)

Publication Number Publication Date
LV10185A LV10185A (lv) 1994-10-20
LV10185B true LV10185B (en) 1995-04-20

Family

ID=10970131

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-627A LV10185B (en) 1986-12-19 1993-06-19 Anti-vomit and sedative preparation for prevention of seasickness

Country Status (26)

Country Link
US (1) US4925878A (lv)
EP (1) EP0294441B1 (lv)
JP (1) JP2534553B2 (lv)
AT (1) ATE82847T1 (lv)
BG (1) BG51918A1 (lv)
CY (1) CY1740A (lv)
CZ (1) CZ277831B6 (lv)
DD (1) DD264851A5 (lv)
DE (1) DE3782935T2 (lv)
DK (1) DK464788A (lv)
ES (1) ES2009228A6 (lv)
FI (1) FI883837A0 (lv)
GE (1) GEP19970949B (lv)
GR (1) GR871953B (lv)
HK (1) HK105193A (lv)
HU (1) HU197510B (lv)
IL (1) IL84786A (lv)
LT (1) LT4007B (lv)
LV (1) LV10185B (lv)
MD (1) MD408C2 (lv)
MX (1) MX9203088A (lv)
PT (1) PT86406B (lv)
RU (1) RU1825314C (lv)
SK (1) SK278500B6 (lv)
UA (1) UA19281A1 (lv)
WO (1) WO1988004552A1 (lv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
CS269271B1 (en) * 1988-05-30 1990-04-11 Hajicek Josef Method of selegiline's hydrochloride production
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
EP0578687A1 (en) * 1991-04-04 1994-01-19 The University Of Toronto Innovations Foundation Use of deprenyl to maintain, prevent loss, or recover nerve cell function
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
ES2149850T3 (es) * 1993-05-04 2000-11-16 Ceva Sante Animale Utilizacion de la selegilina en medicina veterinaria.
FR2704756B1 (fr) * 1993-05-04 1995-07-28 Sanofi Elf Utilisation de la sélégiline en médecine vétérinaire.
GB2280604B (en) * 1993-07-02 1997-04-30 Resource Medical Limited Processing of active agents
DE69520430T2 (de) 1994-06-03 2001-10-18 Jmde Trust Newton Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
WO1996024346A1 (en) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
DE69628415T3 (de) * 1995-03-02 2008-06-26 R.P. Scherer Technologies, Inc., Paradise Valley Arzneimittel enthaltend monoaminooxidase-b-hemmer
DE19716905C1 (de) * 1997-04-22 1998-08-27 Iip Inst Fuer Ind Pharmazie Fo Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung
US6042533A (en) * 1998-07-24 2000-03-28 Kania; Bruce Apparatus and method for relieving motion sickness
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6443913B1 (en) 2000-03-07 2002-09-03 Bruce Kania Apparatus and method for relieving motion sickness
US6497649B2 (en) * 2001-01-21 2002-12-24 University Of Washington Alleviating motion, simulator, and virtual environmental sickness by presenting visual scene components matched to inner ear vestibular sensations
US7128705B2 (en) * 2002-11-26 2006-10-31 Artis Llc Motion-coupled visual environment for prevention or reduction of motion sickness and simulator/virtual environment sickness
AT16235U1 (de) * 2018-06-21 2019-04-15 Dr Reinhart Jarisch Kaugummi enthaltend Vitamin C

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
GB1031425A (en) * 1962-03-30 1966-06-02 Chinoin Gyogyszer Es Vegyeszet New aralkylamines and their preparation
EP0564802B1 (de) 1992-04-10 1996-10-09 Schott Glaswerke Blei- und bariumfreies Kristallglas mit hoher Lichttransmission

Also Published As

Publication number Publication date
ATE82847T1 (de) 1992-12-15
MX9203088A (es) 1992-07-01
SK278500B6 (en) 1997-05-14
CZ277831B6 (en) 1993-06-16
JPH01501626A (ja) 1989-06-08
BG51918A1 (en) 1993-11-15
CY1740A (en) 1995-10-20
EP0294441A1 (en) 1988-12-14
LT4007B (en) 1996-07-25
PT86406B (pt) 1990-11-20
FI883837A (fi) 1988-08-18
UA19281A1 (uk) 1997-12-25
DD264851A5 (de) 1989-02-15
HUT45196A (en) 1988-06-28
DK464788D0 (da) 1988-08-18
CS8709491A1 (en) 1990-05-14
HU197510B (en) 1989-04-28
LV10185A (lv) 1994-10-20
US4925878A (en) 1990-05-15
JP2534553B2 (ja) 1996-09-18
MD408C2 (ro) 1996-07-31
IL84786A (en) 1991-08-16
GR871953B (en) 1988-04-19
RU1825314C (ru) 1993-06-30
EP0294441B1 (en) 1992-12-02
LTIP1849A (en) 1995-08-25
PT86406A (en) 1988-01-01
DE3782935D1 (de) 1993-01-14
GEP19970949B (en) 1997-03-31
DE3782935T2 (de) 1993-04-08
DK464788A (da) 1988-08-18
FI883837A0 (fi) 1988-08-18
HK105193A (en) 1993-10-15
ES2009228A6 (es) 1989-09-16
WO1988004552A1 (en) 1988-06-30

Similar Documents

Publication Publication Date Title
LV10185B (en) Anti-vomit and sedative preparation for prevention of seasickness
Andrews et al. Genetic factors in stuttering confirmed.
HU0201264D0 (lv)
CA2151957A1 (en) Aqueous pharmaceutical preparations of g-csf which are stable in storage
NO942626L (no) Antikorrosive pigmenter
PT71861B (en) Process for preparing long lasting agonists and agonists of lhrh
MY107661A (en) Improved anti-plaque compositions comprising a combination of morpholioamino alcohol and metal salts
GR3025117T3 (en) METHOD FOR PREPARING -g(b)-PHENYLISOSERINE AND ANALOGUES THEREOF.
AU557898B2 (en) Aminoethoxybenzylalcohol derivatives
JPS6470461A (en) Novel pyrrolidine-2,5-dione and 4,5,6,7- tetrahydroisoindole-1,3-dione and herbicidal composition
AU579869B2 (en) 4-amino-8-alkylthio-2-piperazino-pyrimido ``5,4-d`` pyrimidines
Migicovsky Inhibition of cholesterol formation by rat liver homogenates
GR79147B (lv)
KR850001765A (ko) 1-N-(ω-아미노-α-히드록시알카노일)-2',3'-디데옥시프로피온일-2',3'-디데옥시가나마이신 A와 이의 제조방법
NZ245067A (en) Aminotriiodo isophthalic acid dimeric non-ionic compounds, use as x-ray contrast media, and galenic compositions thereof
EP0382635A3 (fr) Utilisation de dérivés d'alkyl-5 pyridazine comme médicaments actifs sur le système cholinergique
WO1998002415A3 (en) Method for inhibiting corrosion and process for preparing 1-amidoalkylimidazoles
Wise Storage period ends for 4000 embryos.
NL8204063A (nl) Farmakologische 4-fenyl-4-oxo-2-buteenzuurderivaten alsmede deze derivaten bevattende farmaceutische preparaten.
AU558329B2 (en) 4-hydroxy-benzhydrol derivatives
Schall Comparison of Medical and Industrial Radiography
Wee Purification, characterization and regulation of testicular temperature labile cholesterol ester hydrolase.
Nakahara et al. Glucosyltransferase inhibitors, as well as dental caries prevention methods and anticarious foods using the same
MX174421B (es) Procedimiento para la preparacion de 4-arilcarbonil-1-[(4-morfolinil)-alquilo-inferior]-1h-indoles y producto obtenido
JPS62652B2 (lv)